The Knowledge Society (TKS) Dubai Edition is Now Accepting Applications for September 2025 Cohort – Apply by July 31, 2025
You're reading Entrepreneur Middle East, an international franchise of Entrepreneur Media.
Dubai Future Foundation and The Knowledge Society (TKS) are now accepting applications for you TKS Dubai, an innovation program designed to equip high-potential students (ages 13–17) with the skills, knowledge, and mindset needed to thrive in a rapidly evolving world.
The Knowledge Society (TKS) – Dubai Edition is a 10-month innovation program that focuses on emerging fields like AI, biotechnology, space, nanotechnology, and more.
It provides cutting-edge knowledge in fields such as artificial intelligence, robotics, and biotechnology — all while connecting students to a global network of mentors, industry leaders, and future-focused thinkers.
In partnership with Dubai Future Foundation, TKS offers up to 30 full scholarships for UAE nationals and merit/need‑based aid for others.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Big Tech may be breaking the bank for AI, but investors love it
By Aditya Soni and Deborah Mary Sophia (Reuters) -Big Tech is spending more than ever on artificial intelligence - but the returns are rising too, and investors are buying in. AI played a bigger role in driving demand across internet search, digital advertising and cloud computing in the April-June quarter, powering revenue growth at technology giants Microsoft, Meta, and Alphabet. Betting that momentum will sustain, Microsoft and Alphabet decided to ramp up spending to ease capacity shortages that have limited their ability to meet soaring AI services demand, even after several quarters of multi-billion-dollar outlays. The results offer the clearest sign yet that AI is emerging as a primary growth engine, although the monetization journey is still in its early days, investors and analysts said. The upbeat commentary also bodes well for the largest U.S. cloud provider, which will report earnings on Thursday after markets close, and underscores how surging demand for the new technology is shielding the tech giants from tariff-driven economic uncertainty hobbling other sectors. "As companies like Alphabet and Meta race to deliver on the promise of AI, capital expenditures are shockingly high and will remain elevated for the foreseeable future," said Debra Aho Williamson, founder and chief analyst at Sonata Insights. But if their core businesses remain strong, "it will buy them more time with investors and provide confidence that the billions being spent on infrastructure, talent and other tech-related expenses will be worthwhile," she added. Microsoft shares rose about 9% in premarket trading on Thursday, putting the Windows maker on track to cross $4 trillion in market value - a milestone only chip giant Nvidia has reached so far. Meta was up even more, rising 11.5% and on course to add nearly $200 billion to its market value of $1.75 trillion. Amazon gained over 3%. All the companies have faced intense scrutiny from investors over their ballooning capital expenditures, which were expected to total $330 billion this year before the latest earnings. And until a few days ago, the Magnificent Seven stocks were also trailing the S&P 500 in year-to-date performance. SILENCING DOUBTS Microsoft said on Wednesday it would spend a record $30 billion in the current quarter, after better-than-expected sales and an above-estimate forecast for its Azure cloud computing business showcased the growing returns on its massive AI bets. The prediction puts Microsoft on track to potentially outspend its rivals over the next year. It came after Google-parent Alphabet beat revenue expectations and raised its spending forecast by $10 billion to $85 billion for the year. Microsoft also disclosed for the first time the dollar figure for Azure sales and the number of users for its Copilot AI tools, whose adoption has long been a concern for investors. It said Azure generated more than $75 billion in sales in its last fiscal year, while Copilot tools had over 100 million users. Overall, around 800 million customers use AI tools peppered across Microsoft's sprawling software empire. "It's the kind of result that quickly silences any doubts about cloud or AI demand," said Josh Gilbert, market analyst at eToro. "Microsoft is more than justifying its spending." Other AI companies have also attracted a clutch of users. Alphabet said last week its Gemini AI assistant app has more than 450 million monthly active users. OpenAI's ChatGPT, the application credited with kicking off the generative AI frenzy, has around 500 million weekly active users. Meta, meanwhile, raised the bottom end of its annual capital expenditure forecast by $2 billion, to a range of between $66 billion and $72 billion. It also said that costs driven by its efforts to catch up in Silicon Valley's intensifying AI race would push 2026 expense growth rate above 2025's pace. Better-than-expected sales growth in the April-June period and an above-estimate revenue forecast for the current quarter, however, assured investors that strength in the social media giant's core advertising business can support the massive outlays. "The big boys are back," said Brian Mulberry, portfolio manager at Zacks Investment Management, which holds shares in all three major U.S. cloud providers. "This simply proves the Magnificent Seven is still magnificent at this moment in time." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
WAVE Life Sciences Ltd (WVE) Q2 2025 Earnings Call Highlights: Progress in RNA Editing Amid ...
Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points WAVE Life Sciences Ltd (NASDAQ:WVE) has made significant progress in RNA editing, particularly with their AATD clinical program and Eli clinical program for obesity. The company has delivered positive data from their forward 53 clinical trial of N531 for DMD, showing statistically significant improvements. WVE 006, their RNA editing oligonucleotide for alpha one antitrypsin deficiency, has shown impressive durability and a favorable safety profile. The company has expanded its second cohort for the WVE 007 obesity program due to favorable safety and robust active reduction. WAVE Life Sciences Ltd (NASDAQ:WVE) has a strong cash position, with $208.5 million in cash and cash equivalents, expected to fund operations into 2027. Negative Points The company's revenue for the second quarter of 2025 decreased to $8.7 million from $19.7 million in the prior year quarter. Research and development expenses increased to $43.5 million, driven by spending in the inhibie program and RNA editing programs. General and administrative expenses rose to $18 million, primarily due to share-based compensation and other external expenses. The net loss for the second quarter of 2025 was $50.5 million, compared to a net loss of $32.9 million in the prior year quarter. There is uncertainty regarding the potential for future milestones and payments under the GSK collaboration, which are not included in the cash runway. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with WVE. Q: For the inhibitE program, can you elaborate on your reasons for expanding cohort 2 over advancing to cohort 3 sooner? If the cohort 2 dose was well tolerated, why not just advance to cohort 3 versus expanding cohort 2? A: We didn't wait to start cohort 3; we're already dosing the 400 mg cohort. The focus on cohort 2 is due to its alignment with our DIO weight loss data and active and knee reduction modeling. Cohort 2 was modeled to align with weight loss similar to semaglutide based on the DIO model. We are encouraged by the clinical translation and are optimistic about the upcoming data readout. Q: Regarding the 006 AGD data readout, what is your guidance on the different expectations from the single-dose to multi-dose data readout? A: We expect larger liver concentration and exposure with the 200 mg multi-dose compared to the 400 mg single dose. We are encouraged by the M protein and total protein levels from the single dose and expect to see more with multi-dosing. The combination of M and total protein will provide good insights, similar to the early single-dose data. Q: On the DMD program, there were updates at the FDA level this morning. Would that affect your approach or strategy with regards to your DMD program? A: Our program goes to Cedar, which has a new division director. This division established the threshold for accelerated approvals for exon-skipping therapies. We are watching the agency's discussions, but there is nothing imminent suggesting changes to our strategy. Q: Can you discuss the extent to which you've focused on optimizing 006 so that it's competitive with others developing RNA editing therapeutics for AATD? A: We've developed 006 to have substantial editing properties that translate from pre-clinical to clinical data. Our optimized chemistry, specifically for Adar editing, and the use of Galnek for efficient delivery, differentiate our approach. This allows for subcutaneous administration and high hepatocyte uptake, distinguishing our program as best in class. Q: Regarding the ATD program, what do you believe the target conversion rate from Z to M should be? Are you looking for a near-complete conversion, or is there an acceptable amount of residual Z protein? A: The goal is to convert ZZ patients to MZ phenotype, providing sufficient protection against hepatic and lung disease. We achieved over 60% edited M protein versus Z with a single dose, which is encouraging. The target is to reach a 50% correction, aligning with the desired MZ phenotype. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Entrepreneur
13 minutes ago
- Entrepreneur
Sharjah Art Foundation Launches 2025-2026 Residency Open Call
Selected residents will have the opportunity to live and work at either Bait Obaid Al Shamsi in Sharjah City or the Kalba Ice Factory in Kalba, during the residency period running from November 2025 to March 2026. You're reading Entrepreneur Middle East, an international franchise of Entrepreneur Media. Sharjah Art Foundation has announced an open call for its 2025–2026 Residency Program, inviting applications from creatives across disciplines, including visual artists, writers, poets, researchers, musicians, performance artists, and filmmakers. The initiative is designed to support experimental and interdisciplinary practices while fostering dialogue and collaboration with Sharjah's dynamic artistic community. Selected residents will have the opportunity to live and work at either Bait Obaid Al Shamsi in Sharjah City or the Kalba Ice Factory in Kalba, during the residency period running from November 2025 to March 2026. The programme offers a comprehensive support package that includes international flights and airport transfers, accommodation, a monthly stipend, and access to the Foundation's extensive institutional networks and resources. Applications are open until 30 August 2025.
